Lantheus (NASDAQ:LNTH) Stock Price Up 6.1%

Lantheus Holdings Inc (NASDAQ:LNTH)’s stock price rose 6.1% on Tuesday . The stock traded as high as $12.00 and last traded at $11.73, approximately 375,556 shares traded hands during mid-day trading. A decline of 21% from the average daily volume of 475,109 shares. The stock had previously closed at $11.06.

LNTH has been the topic of several recent analyst reports. BidaskClub cut Lantheus from a “sell” rating to a “strong sell” rating in a report on Thursday, March 19th. ValuEngine raised Lantheus from a “sell” rating to a “hold” rating in a report on Saturday, February 15th.

The firm has a fifty day simple moving average of $14.78 and a two-hundred day simple moving average of $19.15. The stock has a market cap of $439.27 million, a PE ratio of 14.51 and a beta of 1.46. The company has a current ratio of 2.62, a quick ratio of 2.17 and a debt-to-equity ratio of 1.60.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.04. Lantheus had a return on equity of 45.81% and a net margin of 9.12%. The firm had revenue of $89.35 million for the quarter, compared to analysts’ expectations of $90.62 million. During the same quarter last year, the firm posted $0.29 EPS. The company’s revenue was up 3.6% compared to the same quarter last year.

In other news, CEO Mary Anne Heino sold 6,615 shares of the stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $17.09, for a total transaction of $113,050.35. Following the transaction, the chief executive officer now directly owns 549,399 shares in the company, valued at approximately $9,389,228.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Julie Mchugh sold 1,756 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $15.86, for a total value of $27,850.16. Following the transaction, the director now owns 15,754 shares in the company, valued at $249,858.44. The disclosure for this sale can be found here. Insiders have sold a total of 24,554 shares of company stock worth $396,760 over the last quarter. Corporate insiders own 2.08% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Man Group plc increased its position in shares of Lantheus by 0.5% during the 3rd quarter. Man Group plc now owns 131,899 shares of the medical equipment provider’s stock valued at $3,306,000 after purchasing an additional 650 shares during the last quarter. Sunbelt Securities Inc. bought a new position in Lantheus during the 4th quarter worth approximately $5,128,000. California State Teachers Retirement System grew its position in Lantheus by 1.9% during the 3rd quarter. California State Teachers Retirement System now owns 59,866 shares of the medical equipment provider’s stock worth $1,501,000 after acquiring an additional 1,118 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. grew its position in Lantheus by 13.1% during the 4th quarter. Los Angeles Capital Management & Equity Research Inc. now owns 10,380 shares of the medical equipment provider’s stock worth $213,000 after acquiring an additional 1,203 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in Lantheus by 31.1% during the 4th quarter. SG Americas Securities LLC now owns 6,141 shares of the medical equipment provider’s stock worth $126,000 after acquiring an additional 1,456 shares during the last quarter. Hedge funds and other institutional investors own 97.53% of the company’s stock.

About Lantheus (NASDAQ:LNTH)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Read More: Closed-End Mutual Funds

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.